The Evidence Gap That Doesn’t Close Itself

Right now, in Minneapolis, Chicago, Paris, Boston, Sunnyvale, or any other medtech innovation hub, a commercial and clinical team is sitting on data they can’t use. Outcomes are good. Off-label adoption is real. But none of it is structured or defensible - which means none of it can support a label update, a payer conversation, or more urgently, a commercial differentiator.

The gap between what is happening in the real world: the OR, the hospital, the clinic, or patient homes, and what a company can actually say about it is often years wide. It doesn’t close on its own.

The evidence landscape has moved. Most data strategies haven’t.

The FDA’s December 2025 final guidance — “Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices” — formally expanded the conditions under which real-world data, including data collected as part of routine patient care, can support regulatory submissions and label changes. EU MDR/IVDR imposes post-market follow-up obligations that registries and trials struggle to fulfil. Real world evidence is no longer supplemental. It is becoming a condition of commercial relevance.

And yet most medtech companies are still working from evidence strategies built for a different era: fixed protocols, multi-year enrollment windows, publication lags that arrive after the market has moved, and a single product studied in isolation — when the patient cycle of care is never that simple.

The cost of waiting compounds

Most companies resolve the tension between needing evidence early and lacking the infrastructure to generate it by waiting until post-market pressure builds, until a competitor forces a response. That decision compounds.

 Studies of completed clinical trials consistently show that fewer than half achieve public disclosure of results within four years of completion, with median time from study completion to publication of roughly two years — and industry-funded studies lag significantly longer.¹ A company that starts structured data collection at commercial launch builds an evidence asset that grows with every case, but it isn’t useful until the clinical landscape has already shifted.

What do I think Real World Evidence really means?

It means real patient populations. Not the ones selected by inclusion criteria designed to minimize variance and maximize publication odds. All patients encounter a device - older, sicker, more complex, often managing several conditions at once. The ones prescribed protocol would have excluded.

There is no such thing as a perfect protocol in healthcare. A procedure involves dozens of decisions, which device, which drug, which approach which are made in real time by clinicians working with incomplete information. Evidence that pretends otherwise is evidence that describes a world that doesn’t exist in healthcare.

It means capturing all of that. Every product, drug, and technology used in a procedure — not one device studied in isolation while the rest of the clinical context disappears into a footnote. Outcomes emerge from the combination, not the component.

And it means measuring value in terms that actually matter to the people who bear the consequences: the patient who recovers, the hospital managing the cost, the system absorbing the variation. Not a single endpoint chosen because it could be measured cleanly. The full picture, even where it is inconvenient.

What a different model delivers

A different model collects data continuously, starting from day one of commercial deployment. It captures outcomes across real patient populations — not protocol-selected cohorts — and structures that data at the point of care so it is audit-ready from the moment it is generated. It covers the full procedure context, not a single device in isolation. And it produces usable evidence in months, not years.

Caresyntax RWE collects retrospective and prospective, structured clinical and financial data at the point of care in the OR and throughout the entire cycle of care using a Continuous Quality Improvement methodology that is exempt from IRB and HIPAA consent requirements in most cases. First data arrives in months, not years.

This is a structural feature of the methodology, not a marketing claim. Clinical Quality Improvement (CQI) data is collected as part of routine patient care which is why the FDA has explicitly acknowledged in 510(k) hearings that real-world evidence generated through CQI is important to understanding patient care.

Two commercial partners have already received updated 510(k) clearance using the RWE-generated evidence. One moved from below 10% market access to above 90% within a year of label expansion. They saw a $30 million revenue increase from a single RWE-driven indication update. Another partner had a contraindication removed significantly increasing the application of their technology.

One engagement. Portfolio-level evidence.

Most evidence generation is organized around a single product. But procedures involve combinations of devices, and clinical outcomes emerge from those interactions. RWE captures data across any combination of products used in a procedure enabling portfolio-level evidence without running separate studies for each device. One data collection effort can support multiple regulatory submissions, commercial claims, and payer conversations simultaneously.

The data strategy that compounds

The companies that will lead on evidence in surgical categories are not waiting for post-market problems to force a response. They are building structured data assets from day one of commercialization - assets that adapt to changing regulatory expectations and cover a portfolio, not a single device.

The evidence gap doesn’t close by itself. It either grows or it gets addressed. The cost of addressing it three years later is not just three years of evidence — it is commercial and regulatory ground that moved while the data wasn’t being collected and analyzed.

The path exists. It starts in months.

References :

1.     https://pmc.ncbi.nlm.nih.gov/articles/PMC4098992/